Peripheral Arterial Disease – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of peripheral arterial disease (PAD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PAD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
Clarivate Epidemiology’s PAD forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with PAD?
- Of all people with PAD, how many in each country have been formally diagnosed?
- Of all people diagnosed with PAD, how many in each country are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PAD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 22 PAD patient populations, as follows:
- Total prevalent cases of PAD.
- Total incident cases of PAD.
- Diagnosed prevalent cases of PAD.
- Undiagnosed prevalent cases of PAD.
- Prevalent cases of critical limb ischemia (CLI) with or without rest pain.
- Prevalent cases of undiagnosed CLI with or without rest pain.
- CLI events.
- Diagnosed drug-treated prevalent cases of intermittent claudication (IC) without CLI.
- Diagnosed drug-treated prevalent cases of CLI with or without rest pain.
- Diagnosed non-drug-treated prevalent cases of CLI with or without rest pain.
- … and many more (details available on request).
Note: Coverage may vary by country.
